• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一位住院医生对卵巢癌的看法。

A Resident's Perspective of Ovarian Cancer.

作者信息

Smith Christopher G

机构信息

Department of Obstetrics & Gynecology, University of Kentucky Medical Center, 800 Rose Street, Lexington, KY 40536-0293, USA.

出版信息

Diagnostics (Basel). 2017 Apr 27;7(2):24. doi: 10.3390/diagnostics7020024.

DOI:10.3390/diagnostics7020024
PMID:28448435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5489944/
Abstract

Identifying, understanding, and curing disease is a lifelong endeavor for any medical practitioner. Equally as important is to be cognizant of the impact a disease has on the individual suffering from it, as well as on their family. Ovarian cancer is the leading cause of death from gynecologic malignancies. Symptoms are vague, and the disease is generally at an advanced stage at diagnosis. Efforts have been made to develop methods to identify ovarian cancer at earlier stages, thus improving overall mortality. Transvaginal ultrasound (TVUS), with and without laboratory tests, can be used to screen for ovarian cancer. For over thirty years, the University of Kentucky Markey Cancer Center Ovarian Cancer Screening Program has been studying the efficacy of TVUS for detecting early stage ovarian cancer. After 285,000+ TVUS examinations provided to over 45,000 women, the program has demonstrated that regular TVUS examinations can detect ovarian cancer at early stages, and that survival is increased in those women whose ovarian cancer was detected with screening and who undergo standard treatment. These results demonstrate the utility of TVUS as an efficacious method of ovarian cancer screening.

摘要

对于任何医学从业者来说,识别、理解和治愈疾病都是一项终身的事业。同样重要的是,要认识到疾病对患病个体及其家庭的影响。卵巢癌是妇科恶性肿瘤的主要死因。症状不明确,疾病在诊断时通常已处于晚期。人们一直在努力开发在早期阶段识别卵巢癌的方法,从而提高总体死亡率。经阴道超声检查(TVUS),无论是否结合实验室检查,都可用于筛查卵巢癌。三十多年来,肯塔基大学马基癌症中心卵巢癌筛查项目一直在研究TVUS检测早期卵巢癌的功效。在为超过45000名女性提供了285000多次TVUS检查后,该项目证明定期TVUS检查可以在早期阶段检测出卵巢癌,并且那些通过筛查检测出卵巢癌并接受标准治疗的女性的生存率有所提高。这些结果证明了TVUS作为一种有效的卵巢癌筛查方法的实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/5489944/e993f46443fd/diagnostics-07-00024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/5489944/e993f46443fd/diagnostics-07-00024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ab9/5489944/e993f46443fd/diagnostics-07-00024-g001.jpg

相似文献

1
A Resident's Perspective of Ovarian Cancer.一位住院医生对卵巢癌的看法。
Diagnostics (Basel). 2017 Apr 27;7(2):24. doi: 10.3390/diagnostics7020024.
2
Direct access from general practice to transvaginal ultrasound for early detection of ovarian cancer: a feasibility study.从普通科直接进行经阴道超声检查以早期发现卵巢癌:一项可行性研究。
Scand J Prim Health Care. 2021 Jun;39(2):230-239. doi: 10.1080/02813432.2021.1922831. Epub 2021 Jun 7.
3
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.接受卵巢癌筛查的绝经前后高危女性:焦虑、风险认知与生活质量。
Gynecol Oncol. 2003 Jun;89(3):440-6. doi: 10.1016/s0090-8258(03)00147-1.
4
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.普通人群卵巢癌筛查的死亡率影响、风险及益处:英国卵巢癌筛查协作试验(UKCTOCS)随机对照试验
Health Technol Assess. 2025 May;29(10):1-93. doi: 10.3310/BHBR5832.
5
Systematic evaluation of endometriosis by transvaginal ultrasound can accurately replace diagnostic laparoscopy, mainly for deep and ovarian endometriosis.经阴道超声系统评估子宫内膜异位症可以准确替代诊断性腹腔镜检查,主要用于深部和卵巢子宫内膜异位症。
Hum Reprod. 2021 May 17;36(6):1492-1500. doi: 10.1093/humrep/deab085.
6
Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women.三维超声检查及能量多普勒在无症状围绝经期和绝经后妇女卵巢癌筛查中的应用
Croat Med J. 2005 Oct;46(5):757-64.
7
Validation of an Anti-Müllerian Hormone Cutoff for Polycystic Ovarian Morphology in the Diagnosis of Polycystic Ovary Syndrome in the HARMONIA Study: Protocol for a Prospective, Noninterventional Study.HARMONIA研究中抗苗勒管激素临界值用于多囊卵巢形态学诊断多囊卵巢综合征的验证:一项前瞻性非干预性研究方案
JMIR Res Protoc. 2024 Feb 6;13:e48854. doi: 10.2196/48854.
8
Understanding Patient Preference in Female Pelvic Imaging: Transvaginal Ultrasound and MRI.理解女性盆腔影像检查中的患者偏好:经阴道超声与 MRI。
Acad Radiol. 2018 Apr;25(4):439-444. doi: 10.1016/j.acra.2017.10.011. Epub 2017 Dec 11.
9
Transvaginal US vs. CT in non-pregnant premenopausal women presenting to the ED: clinical impact of the second examination when both are performed.经阴道超声与 CT 在非妊娠绝经前女性就诊 ED 中的应用:两者均进行时第二检查的临床影响。
Abdom Radiol (NY). 2022 Jun;47(6):2209-2219. doi: 10.1007/s00261-022-03504-6. Epub 2022 Apr 8.
10
A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
Cancer. 1993 Jan 15;71(2 Suppl):589-93. doi: 10.1002/cncr.2820710215.

引用本文的文献

1
The role of RNA methyltransferase METTL3 in gynecologic cancers: Results and mechanisms.RNA甲基转移酶METTL3在妇科癌症中的作用:结果与机制
Front Pharmacol. 2023 Mar 16;14:1156629. doi: 10.3389/fphar.2023.1156629. eCollection 2023.
2
Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer.卵巢癌的病因、流行病学、组织病理学、分类、详细评估及治疗
Cureus. 2022 Oct 21;14(10):e30561. doi: 10.7759/cureus.30561. eCollection 2022 Oct.
3
Dysregulation of lncRNA-miRNA-mRNA Interactome as a Marker of Metastatic Process in Ovarian Cancer.

本文引用的文献

1
Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.浆液性输卵管上皮内癌伴卵巢外转移
Int J Gynecol Cancer. 2017 Mar;27(3):444-451. doi: 10.1097/IGC.0000000000000920.
2
The disparate origins of ovarian cancers: pathogenesis and prevention strategies.卵巢癌的不同起源:发病机制和预防策略。
Nat Rev Cancer. 2017 Jan;17(1):65-74. doi: 10.1038/nrc.2016.113. Epub 2016 Nov 25.
3
Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies.非上皮性卵巢癌:解析罕见的妇科恶性肿瘤
lncRNA-miRNA-mRNA相互作用组失调作为卵巢癌转移过程的标志物
Biomedicines. 2022 Mar 31;10(4):824. doi: 10.3390/biomedicines10040824.
4
Identification of the Mutational Landscape of Gynecological Malignancies.妇科恶性肿瘤突变图谱的鉴定
J Cancer. 2020 Jun 8;11(16):4870-4883. doi: 10.7150/jca.46174. eCollection 2020.
5
Ovarian Cancer Screening: Lessons about Effectiveness.卵巢癌筛查:关于有效性的经验教训
Diagnostics (Basel). 2017 Dec 29;8(1):1. doi: 10.3390/diagnostics8010001.
6
Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancer.副肿瘤抗原作为卵巢癌早期诊断的生物标志物
Gynecol Oncol Rep. 2017 Jun 15;21:37-44. doi: 10.1016/j.gore.2017.06.006. eCollection 2017 Aug.
Anticancer Res. 2016 Oct;36(10):5031-5042. doi: 10.21873/anticanres.11072.
4
Epidemiology of epithelial ovarian cancer.上皮性卵巢癌的流行病学
Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. Epub 2016 Oct 3.
5
Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.PLCO试验中卵巢癌筛查的延长死亡率结果,中位随访时间为15年。
Gynecol Oncol. 2016 Nov;143(2):270-275. doi: 10.1016/j.ygyno.2016.08.334. Epub 2016 Sep 9.
6
Large ovarian cancer screening trial shows modest mortality reduction, but does not justify population-based ovarian cancer screening.大型卵巢癌筛查试验显示死亡率有适度降低,但并不支持基于人群的卵巢癌筛查。
Evid Based Med. 2016 Aug;21(4):159. doi: 10.1136/ebmed-2016-110411. Epub 2016 Jul 22.
7
Current clinical application of serum biomarkers to detect ovarian cancer.血清生物标志物在卵巢癌检测中的当前临床应用。
Prz Menopauzalny. 2015 Dec;14(4):254-9. doi: 10.5114/pm.2015.55887. Epub 2015 Nov 27.
8
Cancer statistics, 2016.癌症统计数据,2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
9
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.英国卵巢癌筛查协作试验(UKCTOCS)中的卵巢癌筛查与死亡率:一项随机对照试验
Lancet. 2016 Mar 5;387(10022):945-956. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17.
10
Diagnosis of ovarian cancer.卵巢癌的诊断
BMJ. 2015 Sep 1;351:h4443. doi: 10.1136/bmj.h4443.